#AI Governance #Life Sciences #Responsible AI

Industry Report Highlights Importance of AI Governance in Life Sciences

The latest findings from the Responsible AI in Life Sciences (RAIL) Report 2026 unveil a proactive shift among life sciences leaders towards implementing crucial governance structures as a means to responsibly scale agentic AI across commercial, medical, and patient-facing domains. The report, conducted by ACTO, synthesizes insights from numerous executive roundtables and a comprehensive survey with senior leaders in the pharmaceutical, biotech, and medical device sectors.

The Current Landscape of AI Governance

The findings indicate that a robust 64% of the surveyed leaders affirm their organizations either have a fully established AI governance process or are actively developing one. The emphasis on governance reflects a broader awareness of the ethical implications tied to AI utilization, with an overwhelming 81% of leaders categorizing responsible AI as validated, 79% as ethical, and 75% as safe—characteristics paramount in a field that prioritizes patient welfare.

However, despite the optimistic trends, a significant gap remains: more than one-third of organizations lack a defined governance strategy, often resorting to a one-time IT approval process. This shortcoming presents a potential risk in fostering a trustworthy environment for AI deployment—an endeavor heavily reliant on establishing user trust.

Trust as a Barrier to AI Scale

The survey reveals that trust emerges as a pivotal element influencing AI adoption within life sciences. While 69% of leaders consider themselves personally comfortable with AI technologies, a notable 54% express reservations regarding how AI is being operationalized in their own organizations. This discord underscores a critical inconsistency, suggesting that while organizational leaders are keen to utilize AI, hesitations remain centered around responsible execution.

Interestingly, the report highlights that most leaders (68%) are already engaged in an AI project, yet trust remains a defining measure of success, positioned above operational efficiency in considerations for pilot projects. When elucidating the criteria for judging AI pilots, 24% noted trust and adoption, outpacing efficiency ratings.

Governance as a Framework for Trust

Our analysis indicates that leaders are beginning to reconceptualize AI governance not merely as a prerequisite but as an enduring framework requiring support and oversight long after initial deployments. Effective governance must encompass designated business owners, comprehensive standard operating procedures (SOPs), and a clear escalation pathway for issues arising during AI deployment.

A critical area of discussion at the RAIL roundtables was the ownership of AI agent actions. Opinions varied, with 34% attributing accountability to the end user, followed closely by legal and compliance teams (28%). This uncertainty complicates the establishment of a coherent governance model, with many organizations struggling to monitor the use of unauthorized AI systems—23% admitted they do not actively track employee utilization of such resources.

Moving Forward: Establishing Common Standards

To advance the dialogue surrounding AI governance, the RAIL Score has been introduced, offering a clear grading system for agentic AI across six essential components: governance, security, testing and certification, human-centricity, value creation, and orchestration. This framework not only allows for better assessment of AI systems but also empowers organizations to align with the stringent standards necessary for regulated industries, fostering trust built on measurable evidence rather than mere vendor claims.

The report brings to light that life sciences organizations are evolving from merely contemplating AI’s use to defining its future applications. Four in five leaders agree that AI risks and ROI assessments should be weighed against existing human-led operations, thereby prompting a re-evaluation of how AI roles should intertwine with human judgment—the qualities of human connection, strategic thinking, and problem-solving will be indispensable as the industry navigates this shift.

Conclusion

The RAIL Report 2026 plays a crucial role in illuminating the paths ahead for organizations eager to harness AI responsibly while addressing the ethical challenges tied to its deployment. As the life sciences industry grapples with these realities, it is evident that establishing a consistent governance framework will be key to unlocking AI’s transformative potential for patient-centric advancements. For those interested in a deeper dive into the report's findings, registration for the webinar